{"id":583633,"date":"2026-08-13T16:38:10","date_gmt":"2026-08-13T16:38:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/583633\/"},"modified":"2026-08-13T16:38:10","modified_gmt":"2026-08-13T16:38:10","slug":"glp-1-linked-to-lower-cardiovascular-risk","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/583633\/","title":{"rendered":"GLP-1 Linked to Lower Cardiovascular Risk"},"content":{"rendered":"<p>ANOTHER <a href=\"https:\/\/www.emjreviews.com\/diabetes\/news\/glp-1-use-linked-to-breast-cancer-survival-in-patients-with-diabetes\/?_rt=NHwxfGdscC0xfDE3ODY0NTI4Mzc&amp;_rt_nonce=b75e014129\" rel=\"nofollow noopener\" target=\"_blank\">GLP-1 drug<\/a> has been associated with a lower risk of major adverse cardiovascular events compared with alternative treatment, a new study shows.<\/p>\n<p>The study showed Tirzepatide, a dual incretin agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors, reduced the risk by 32% compared to sitagliptin.<\/p>\n<p>Reduction of MACE, Infection and Hospitalisation <\/p>\n<p>The study included 52,971 adults in the USA with both Type 2 <a href=\"https:\/\/www.emjreviews.com\/diabetes\/article\/personalising-exercise-and-nutrition-behaviours-in-diabetes-lifestyle-prevention\/?_rt=NHwxfGRpYWJldGVzfDE3ODY0NTI3OTQ&amp;_rt_nonce=5b822fa16a\" rel=\"nofollow noopener\" target=\"_blank\">diabetes<\/a> and established atherosclerotic cardiovascular disease (ASCVD), of whom 17,618 were treated with sitagliptin placebo proxy, and 35,353 initiated tirzepatide.<\/p>\n<p>After one year, 2.9% of people taking tirzepatide experienced a major cardiovascular event (MACE), compared with 4.4% of those taking sitagliptin.<\/p>\n<p>This means that people taking tirzepatide had about a 32% lower risk of MACE compared with those taking sitagliptin. In practical terms, for every 70 people treated with tirzepatide instead of sitagliptin, one additional major cardiovascular event was prevented.<\/p>\n<p>When the researchers looked at individual cardiovascular events, tirzepatide was linked to a lower risk of heart attack. However, there was no clear difference in the risk of ischaemic stroke between the two groups.<\/p>\n<p>Tirzepatide was also associated with fewer infections requiring hospital treatment. For every 48 people treated with tirzepatide instead of sitagliptin, one hospitalisation for infection was prevented.<\/p>\n<p>There were also fewer deaths caused by infection among people taking tirzepatide, as well as fewer deaths overall.<\/p>\n<p>The researchers also looked at unrelated health conditions as a way of checking whether the results could be explained by other factors. They found no meaningful link between tirzepatide and these conditions.<\/p>\n<p>More Evidence for GLP-1s and Cardiovascular Disease<\/p>\n<p>The findings of the study suggest that tirzepatide may have effects beyond its impact on blood sugar, weight, and traditional cardiovascular risk factors by contributing to a lowered risk of infection related hospitalisation and mortality.<\/p>\n<p>However, because this was a study based on real-world patient data rather than a randomised clinical trial, the findings cannot prove that tirzepatide directly caused these improvements.<\/p>\n<p>Whilst results between treatments vary, these latest findings as fairly to a growing body of evidence backing GLP-1s to reduce the risk of cardiovascular disease whilst supporting weight loss in people with Type 2 diabetes and established cardiovascular risk, as well as in people with obesity and cardiovascular disease without diabetes.<\/p>\n<p>Reference<\/p>\n<p>Kr\u00fcger N et al. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ. 2026;394:e100011<\/p>\n<p>Featured Image: sebra on Adobe Stock<\/p>\n","protected":false},"excerpt":{"rendered":"ANOTHER GLP-1 drug has been associated with a lower risk of major adverse cardiovascular events compared with alternative&hellip;\n","protected":false},"author":2,"featured_media":583634,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-583633","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/583633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=583633"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/583633\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/583634"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=583633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=583633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=583633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}